Managed Care
Disease
Management

2 Lenalidomide Regimens in The FIRST Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma Patients: Initial Phase 3 Results

Thierry Facon, MD, of Hopital Claude Huriez, CHRU Lille in France, concludes that in newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation, the FIRST trial establishes continuous lenalidomide therapy as a new standard of care.